738 related articles for article (PubMed ID: 16353204)
1. Metastatic osteosarcoma.
Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
[TBL] [Abstract][Full Text] [Related]
2. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
4. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
Bacci G; Mercuri M; Briccoli A; Ferrari S; Bertoni F; Donati D; Monti C; Zanoni A; Forni C; Manfrini M
Cancer; 1997 Jan; 79(2):245-54. PubMed ID: 9010097
[TBL] [Abstract][Full Text] [Related]
5. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
6. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
Seibel NL; Krailo M; Chen Z; Healey J; Breitfeld PP; Drachtman R; Greffe B; Nachman J; Nadel H; Sato JK; Meyers PA; Reaman GH
Cancer; 2007 Apr; 109(8):1646-53. PubMed ID: 17334983
[TBL] [Abstract][Full Text] [Related]
7. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
12. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
16. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
17. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
19. [Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report].
Fujita H; Kiyokawa N; Takada K; Kyo K; Ishimoto K; Yabuta K; Mizuno T
Gan To Kagaku Ryoho; 1991 Sep; 18(12):2167-70. PubMed ID: 1888188
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
